our ceo is waiting for the data from the four ongoing trials to seal a deal with Gilead, but she should make it clear to the SHs.
When all were busy finding vax, our ceo was busy taking two+ years for mouse model. What else can we expect from our ceo who does not have any proactive plan for prompt funding and swift trial design teams, …..
Top holders need to act to topple the ceo whose mouse model is not enticing anyone. Some antivirals are already in the market, Biotron and Gilead must come up with an antiviral to compete with others.
Something going on behind the scene, which is highly likely to increase the SP. we want prompt actions and re deal.
Ann: POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM, page-472
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
